3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Radiation Injuries
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
51
Carboplatin
21
Paclitaxel
20
Cyclophosphamide
18
Nivolumab
13
Taxes
10
130-nm albumin-bound paclitaxel
10
olaparib
9
Specimen Handling
9
spartalizumab
8
fludarabine
8
Doxorubicin
8
durvalumab
7
Magnetic Resonance Spectroscopy
7
Gemcitabine
7
Cisplatin
7
Biopsy
7
veliparib
6
atezolizumab
6
Fulvestrant
6
Albumin-Bound Paclitaxel
6
liposomal doxorubicin
5
eribulin
5
budigalimab
5
Irinotecan
5
Ipilimumab
5
aldesleukin
4
Radiotherapy
4
Oxaliplatin
4
Leucovorin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Triple Negative Breast Neoplasms
×
Adenosine Diphosphate Ribose
×
Clear all
NCT03109080
2025-11-24
RadioPARP
Institut Curie
Phase 1
Completed
24 enrolled